Silibinin attenuates amyloid β25-35 peptide-induced memory impairment

• 作 者: BiaoZhou[1]XiaoyuSong[1]PingpingZhang[1]DiLei[1]MingyuXia[1]ToshihikoHayashi[1]TakashiIkejima[2]
• 机 构: China-Japan Research Institute of Medical and Pharmaceutical Sciences,Shenyang Pharmaceutical Univer
• 出 处: 2015全国老年痴呆与认知障碍相关疾病学术大会
• 发表日期: 2015年期

　　This study aimed to investigate whether silibinin could improve the learning and memory, and antioxidant abilities of Alzheimer's diseases (AD) rats.The 60 rats were randomly divided into six groups: normal control group, AD model group, low-dose silibinin group, middle-dose silibinin group, high-dose silibinin group and positive control group (donepezil).Treatment of silibinin orally improved Aβ25-35-induced loss of weight and inhibited spleen index.Silibinin decreased Aβ25-35-induced elevations of the escape latency and the searching distance and reversed the decrease in crossing numbers.